A Glasgow academic has founded a new longevity and ‘healthspan’ firm which will use the power of AI to detect early signs of Alzheimer’s, cancer and heart disease.
Entourage AI uses complex algorithms to analyse thousands of human proteins from a simple blood test to predict disease in later life.
The company, founded by University of Glasgow professor Patrick T. Gunning, announced a £3.75 million pre-seed raise on Wednesday alongside the opening of its new research and operations centre in Glasgow.
The firm has also developed an Aging Clock and AI Coach, which helps users understand their biological age against their chronological age, and make interventions if there are any health concerns. The firm claims that some of the interventions may even help slow, or possibly reverse the aging process.
Professor Gunning said: “Our mission at Entourage AI is to transform how we measure and understand human health. By harnessing advanced proteomics and AI, we can move beyond reactive medicine toward earlier detection, more precise insights, and truly personalised care.”
Business minister Richard Lochhead said: “The technology being developed by Entourage AI illustrates how artificial intelligence can be used to transform healthcare – both here and across the world.
“As a Scottish-rooted spinout from the University of Glasgow, I am delighted that Entourage AI has secured such a significant raise and wish the company every success as it moves into its new research and operations centre and begins taking orders across its latest products.”
The platform is built on Entourage AI’s proprietary ‘reference model’ of a healthy proteome, developed from mass spectrometry–based analyses of thousands of individuals aged 16 to 85. Using this dataset, which includes measurements of human proteins and millions of peptides, the system estimates biological age and provides organ-specific health insights.
Preorders are available now to consumers in UK and USA, as well as to research institutions, longevity clinics, health systems, and enterprise partners. Early participants will receive priority access to testing cohorts, collaborative research programs, API integration, and deployment options.
The funding round was led by Provision, with investment also coming from GU Holdings Ltd, healthtech investors David Peterson and Brad Peltz, and other angel investors.
